NEW YORK, March 28, 2014 /PRNewswire/ -- Amarin
Corporation plc (NASDAQ: AMRN), an established biopharmaceutical
company focused on the commercialization and development of
therapeutics to improve cardiovascular health is in the process of
attempting a turnaround to return to a growth
trajectory. The Company's lead product, Vascepa
(icosapent ethyl) capsules, is approved by the U.S. FDA for use as
an adjunct to diet to reduce triglyceride levels in adult patients
with severe hypertriglyceridemia.
Amarin's lead product is FDA approved and generating revenue in
the marketplace. Initiatives are underway to overcome recent
regulatory hurdles and expand approved indications for the drug
which could drive accelerated revenues going forward.
GlaxoSmithKline markets a competing and very comparable compound
called Lovaza that has validated the available market. Lovaza is
estimated to generate about $1
billion in annual sales. Lovaza has recently come off
patent and competition in the segment is likely to pick up
meaningfully going forward with substantial market share up for
grabs.
An analyst report which details key attributes of the
technology, an overview of the company and analyst recommendation
can be viewed in its entirety by using the link below. There is no
cost, email entry or obligation required to view this report:
http://bit.ly/-AMRN-CFA-Report
copy and paste to browser may be required.
FORWARD-LOOKING DISCLAIMER
This report may contain certain forward-looking statements and
information, as defined within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, and is subject to the Safe Harbor created by those
sections. This material contains statements about expected future
events and/or financial results that are forward-looking in nature
and subject to risks and uncertainties. Such forward-looking
statements by definition involve risks, uncertainties and other
factors, which may cause the actual results, performance or
achievements of mentioned company to be materially different from
the statements made herein.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is written and authored by
Michael Andereg, Chartered Financial Analyst. An outsourced
research services provider represented by Michael Andereg,
Chartered Financial Analyst provided Small Cap Street, LLC this
article or report. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below. Small Cap Street, LLC and BrokerBank Securities, Inc. are
not entitled to veto, interfere or alter the articles, documents or
report once created and reviewed by the outsourced research
provider represented by Michael Andereg, Chartered Financial
Analyst.
If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at admin@smallcapstreet.com. For any urgent concerns or inquiries,
please contact us at admin@smallcapstreet.com.
AMRN has not compensated Small Cap Street, LLC, BrokerBank
Securities, Inc., and Michael Andereg, Chartered Financial Analyst
for the creation or dissemination of this report. Small Cap Street,
LLC, BrokerBank Securities, Inc., and Michael Andereg, Chartered
Financial Analyst do not own shares in AMRN. Small Cap Street, LLC
and BrokerBank Securities, Inc., is not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by
Small Cap Street, LLC and BrokerBank Securities, Inc. whatsoever
for any direct, indirect or consequential loss arising from the use
of this document. Small Cap Street, LLC and BrokerBank Securities,
Inc. expressly disclaims any fiduciary responsibility or liability
for any consequences, financial or otherwise arising from any
reliance placed on the information in this document. Small Cap
Street, LLC and BrokerBank Securities, Inc. do not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
Small Cap Street, LLC is the party responsible for hosting the
full analyst report on smallcapstreet.com. BrokerBank Securities in
the party responsible for issuing the press release and Michael
Andereg, Chartered Financial Analyst is the author of research
report. Information in this release is fact checked and
produced on a best efforts basis by Michael Andereg, Chartered
Financial Analyst. BrokerBank Securities, Inc. has been compensated
one hundred dollars by Small Cap
Street, LLC to issue press release. Michael Andereg, Chartered
Financial Analyst has been compensated two hundred by Small Cap
Street, LLC for the right to disseminate press release and research
report.
BrokerBank Securities, Inc. is a member of the Financial
Industry Regulatory Authority, CRD number #130116
SOURCE BrokerBank Securities, Inc.